The efficacy and tolerability of auto-stimulation-VNS in children with Lennox-Gastaut syndrome

ObjectiveLennox-Gastaut syndrome (LGS) is a severe drug-resistant epilepsy (DRE) of childhood. The Vagus Nerve Stimulator (VNS) established as safe and effective treatment for DRE. This study assesses efficacy tolerability the auto-stimulation VNS models in pediatric patients with LGS.MethodsThis retrospective chart review cohort (Age 1–18 years old) LGS implanted an model at single level four center. Patient responder’s rate was measured seizure reduction over baseline improvements five quality-of-life measures reported by families. Efficacy were assessed 1, 3, 6, 12, 18 24 months compared to baseline.ResultsThis includes 71 consecutive children Lennox-Gastaut who underwent implantation one two VNS. average age 20.82 months. Of those patients, 55 % achieved greater than 50 six months, 67.7 12 65 At 11 completely free 17 free. By post most patient families least improvement or more measures. commonly adverse events dysphonia, paresthesia, shortness breath, all which tolerated subsided months.SignificanceThis provides evidence that paradigm based on detection tachycardia are well population LGS. Furthermore, this shows population, may provide additional benefits earlier versions.